However, since MM cells generally overexpress MCL-1 [20] and require MCL-1 for survival [21,22], several BH3-mimetics targeting this anti-apoptotic protein have been recently developed [23,24,25] and are currently being tested in preclinical and early phase clinical trials. The gene discussed is MCL1; the disease is Miyoshi myopathy.